Treatment of colorectal cancer liver metastases;Il trattamento delle metastasi epatiche da cancro del colon-retto

Minerva Medica

Volumn 97, Issue 1, 2006, Pages 107-119

  Derenzini, E ^a   Di Battista, M ^a   Di Marco, M C ^a   Dell'Arte, S ^a   Astorino, M ^a   Bertolini, S ^a   Brandi, G ^a   Biasco, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 Fluorouracil; Colonic neoplasms, therapy; Irinotecan; Liver metastases; Oxaliplatin; Rectal neoplasms, therapy

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE; IRINOTECAN; OXALIPLATIN;

CHEMOTHERAPY; COLORECTAL CANCER; CRYOSURGERY; HUMAN; LIVER METASTASIS; RADIOFREQUENCY ABLATION; RECURRENT CANCER; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DECISION TREES; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 33646337161     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin N Am 2002;82:1075-90.
2. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405-10.
3. Wanebo HJ, Semoglou C, Attiyeh F, Stearns MJ Jr. Surgical management of patients with primari operable colorectal cancer and syncronous liver metastases. Am J Surg 1978;135:81-5.
4. Pichlmayr R. Is there a place for liver grafting for malignancy? Transpl Proc 1988;20:478-82.
5. Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975-9, discussion 979-80.
6. Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998;66:214-8, discussion 218-9.
7. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000;232:777-85.
8. Ercolani G, Grazi GL, Ravaioli M, Cescon M, Gardini A, Varotti G et al. Liver Resection for multiple colorectal metastases: influence of parenchymal involment and total tumor volume, vs number or location, on long-term survival. Arch Surg 2002;137:1187-92.
9. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P et al. Surgical resection of colorectal carcinoma to the liver. Cancer 1996;77:1254-62.
10. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Analysis of 1001 consecutive cases. Arm Surg 1999;230:309-18; di scussion 318-21.
11. Wein A, Riedel C, Bruckl W, Merkel S, Ott R, Hanke B et al. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and Oxaliplatin in Patients with primary resectable liver metastases of colorectal cancer. Oncology 2003;64: 131-8.
12. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.
13. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-7.
14. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;182938-47.
15. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681-6.
16. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
17. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
18. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
19. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
20. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S et al. Italian Trials in Medical Oncology (ITMO) Group. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004;100:279-87.
21. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;20:4006-14.
22. Souglakos J, Mavroudis D, Kakolyris S, Kourousis Ch, Vardakis N, Androulakis N et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002;20:2651-7.
23. Hurwitz H, Ferhenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl Med 2004;350:2335-42.
24. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-20; discussion 520-2.
25. Wein A, Riedel C, Kockerling F, Martus P, Baum U, Brueckl WM et al. Impact of surgery in palliative patiens with metastatic colorectal cancer after first line-treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 2001;12:1721-7.
26. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-Fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9.
27. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and fluorouracil plus folinic acid in colorectal cancer liver metastases. Ann Oncol 2004;15:933-9.
28. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001;19:2687-95.
29. Leonard GD, Fong Y, Jarnagin R, Harris, L. Schwartz, M. D'Angelica et al. Liver resection after hepatic arterial infusion plus systemic Oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases. J Clin Oncol 2004; 22:(15 Supplement):3542.
30. Janinis J, Papakostas P, Samelis G, Skarios D, Papagianopoulos P, Fountzilas G. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 2000;11:163-7.
31. Kouroussis C, Souglakos J, Mavroudis D, Papadouris S, Kakolyris S, Agelaki S et al. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Am J Clin Oncol 2002;25:627-31.
32. Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC et al. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest 2003;21:505-11.
33. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-09.
34. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-7.
35. Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001;12:1269-72.
36. Stickel F, Jungert B, Brueckl V, Schirner I, Brueckl WM, Mannlein G et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pretreated with AIO plus oxaliplatin. Anticancer Drugs 2003;14:745-9.
37. Tai CJ, Liu JH, Chen WS, Lin JK, Wang WS, Yen CC et al. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. Jpn J Clin Oncol 2003;33:136-40.
38. Mabro M, Louvet C, Andre T, Carola E, Gilles-Amar V, Artru P et al. Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 2003;26:254-8.
39. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77: 1241-6.
40. Pearson AS, Izzo F, Fleming D, Ellis LM, Delrio P, Roh MS et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999;178:592-9.
41. Bilchik AJ, Wood TF, AUegra D, Tsioulias GJ, Chung M, Rose DM et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000;135: 657-62.
42. Adam R, Hagopian E, Linhares M, Krissat J, Savier E, Azoulay D et al. A comparison of percutaneus cryosurgery and percutaneus radiofrequency for unresectable hepatic malignancies. Arch Surg 2002;137: 1332-9.
43. Bleicher R, Allegra D, Nora D, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lesson learned. Arch Surg Oncol 2003;10:52-8.
44. Solbiati L, Livraghi T, Goldberg S, Ierace T, Meloni F, Dellanoce M et al. Percutaneus radiofrequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159-66.
45. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-25.
46. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary collorectal liver metastases. Br J Surg 2003;90:1240-3.
47. Rothbarth J, Tollenaar RAEM, Schellens JHM, Nortier JWR, Schultze Kool LJ et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer 2004;40:1812-24.
48. Alexander HR, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T. Isolated Hepatic Perfusion for the Treatment of Patients With Colorectal Cancer Liver Metastases After Irinotecan-Based Therapy. Ann Surg Oncol 2005;12:138-44.
49. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001;129: 176-87.
50. Alexander HR, Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C et al. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer 2002;95:730-6.
51. Lorenz M, Muller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998;228:756-02.
52. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.
53. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
54. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S et al. Combined modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy- An intergroup study. J Clin Oncol 2002;20:1499-505.
55. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001;88:980-5.
56. th National Congress of Medical Oncology 21-24 September, 2004: Bologna, Italy. Session of Oral Communications on Colorectal Cancer, Sept 23, 2004. Abstract E38.
57. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987;11:541-7.
58. Petrowsky H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer. Ann Surg 2002;235: 863-71.
59. Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003;238:871-83, discussion 883-4.
60. Biasco G, Gallerani E. Treatment of liver metastases from colorectal cancer: what is the best approach today? Dig Liver Dis 2001;33:438-44.